Treating idiopathic pulmonary fibrosis: current opportunities and future challenges

Authors


  • Conflict of interest

    Luca Richeldi reports receiving consulting fees from Boehringer Ingelheim, Intermune, Celgene, Sanofi, Anthera and Gilead; lecture fees from Intermune.

Correspondence

Luca Richeldi, MD, PhD, Center for Rare Lung Diseases, University Hospital of Modena, Via del Pozzo 71, 41124

Modena, Italy.

Tel: +39 059 4222198

Fax: +39 059 4224231

email: luca.richeldi@unimore.it

No abstract is available for this article.

Ancillary